Adenovirus Protein Triggers VITT, Albemarle Slashes Kemerton Operations, Rhode Debuts in Australia, Barbeques Galore Enters Receivership, and more...
Australia Daily News · brief.news
February 12, 202610m 15s
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(0:10): Study Pinpoints Adenovirus Protein as Trigger for Rare Vaccine-induced Clotting Disorder VITT
(2:22): Albemarle Idles Kemerton Plant Amid Market Challenges, Aims for Cost Cuts and Flexibility
(4:37): Hailey Bieber's Beauty Brand Rhode Debuts in Australia with Sydney Pop-Up and Celebrity Buzz
(6:27): Barbeques Galore Enters Receivership, 500 Jobs at Risk Amid Restructuring Efforts
(8:09): Scotty James Poised for Gold in Milano Cortina 2026 Halfpipe Showdown
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: Mathrubhumi English
(2:22): Albemarle Idles Kemerton Plant Amid Market Challenges, Aims for Cost Cuts and Flexibility
(4:37): Hailey Bieber's Beauty Brand Rhode Debuts in Australia with Sydney Pop-Up and Celebrity Buzz
(6:27): Barbeques Galore Enters Receivership, 500 Jobs at Risk Amid Restructuring Efforts
(8:09): Scotty James Poised for Gold in Milano Cortina 2026 Halfpipe Showdown
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: Mathrubhumi English
Topics
VITTPF4 antibodiesadenovirus pVII proteinmolecular mimicryvaccine safetyadenovirus-based vaccinesrisk mitigationprecision vaccinologydiagnosticsimmunologynejm VITT findingsgenetic susceptibilityIGLV3.21*02proteomicsstructural analysispublic confidencesafety surveillancebiosafetycase contextAustralia vaccine rolloutVITT payoutspolicy discussionvaccination messagingneurovascular thrombosisblood clotting disordersclinical risk monitoringMass spectrometry sequencingmolecular triggeradeno-associated virusVITT antibodiesrisk assessmentsafer vaccine designvaccine translationtherapeutic strategiesdiagnostic pathwayspreventive strategiescase impactAustalian deathssurveillance systemspublic health policy